论文部分内容阅读
目的观察生长抑素类似物奥曲肽治疗晚期原发性肝癌的临床疗效和安全性,并探讨其作用机制。方法对36例晚期原发性肝癌患者使用奥曲肽0.1 mg皮下注射,每12 h一次,连用2个月,同时接受积极支持治疗。观察患者一般状况及不良反应,检测血常规﹑肝功能及血清AFP滴度﹑免疫学指标等的变化情况,并进行密切随访。结果治疗前后患者的血常规﹑肝功能无明显变化,血清甲胎蛋白明显下降,细胞免疫功能提高,疼痛减轻,食欲有所好转,消化道出血风险降低,生活质量明显提高。结论生长抑素类似物奥曲肽在延长晚期原发性肝癌患者生存时间,改善生活质量,提高生存率等方面有较好的疗效,不良反应轻,值得临床进一步深入研究。
Objective To observe the clinical efficacy and safety of the somatostatin analogue octreotide in the treatment of advanced primary hepatocellular carcinoma (HCC) and to explore its mechanism. Methods 36 patients with advanced primary liver cancer were injected subcutaneously with octreotide 0.1 mg once every 12 hours for 2 months and received active supportive therapy. The general condition and adverse reactions were observed. The changes of blood and liver function, serum AFP titer and immunological indexes were observed and followed up closely. Results Before and after treatment, there was no significant change of blood and liver function, serum alpha-fetoprotein, cellular immunity, alleviation of pain, improvement of appetite, lower risk of gastrointestinal bleeding and improvement of quality of life. Conclusion The somatostatin analogue octreotide is effective in prolonging the survival time, improving the quality of life and improving the survival rate of patients with advanced primary liver cancer. The adverse reactions are light and worth further study in clinic.